The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2013A New Tool for CSF-Based Parkinson Disease Diagnostics: Super-Resolution Microscopy Investigation of Alpha-Synuclein Aggregates
Objective/Rationale:
It is still difficult to diagnose Parkinson’s Disease (PD) patients through routine assays. Clinical research on PD suggests that the aggregation (clumping) of the... -
Target Validation, 2013Validation of the Transcriptional Repressor Bach1 as a Novel Target to Enhance Antioxidant Response Pathway and Block Neurodegeneration in Parkinson’s Disease
Objective/Rationale:
Bach1 is a transcriptional repressor, which is a protein that binds to a specific DNA site and prevents transcription of nearby genes. Bach1 is primarily localized to... -
RRIA (Rapid Response Innovation Awards), 2013Proof-of-concept Study for the Development of Non-invasive Immunotherapy for Parkinson’s Disease: Intranasal Targeting of Immunoglobulin G Antibodies and Fragments to the CNS
Objective/Rationale:
Immunotherapy using antibodies directed against alpha-synuclein is an extraordinarily promising, potentially disease-modifying treatment approach for Parkinson’s... -
LRRK2 Challenge, 2013LRRK2 and Vitamin D3 Metabolism
Objective/Rationale:
The LRRK2 kinase enzyme is mutated in some patients with Parkinson’s disease (PD). Coincidentally, the kinase is widely expressed in most organs of the body. We... -
Target Validation, 2013Significance of Miro in the Pathogenesis of Parkinson's Disease
Objective/Rationale:
Miro is a protein on the outer membrane of mitochondria. Miro anchors kinesin motor proteins to mitochondria; the kinesins transport mitochondria to where they need... -
MJFF Research Grant, 2013Characterization of LRRK2 Inhibitors for Advanced Drug-like Properties
Objective/Rationale:
Zenobia Therapeutics has identified a unique series of highly specific and potent LRRK2 inhibitors with central nervous system drug-like chemical properties using the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.